Kornimate/medical-research-clean huggingface dataset:
renin and prorenin in pregnancy

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Pregnancy Toxemias; Pre-Eclampsia

Summary: to determine the role of the prorenin-renin-angiotensin-aldosterone system (raas) in normal and hypertensive pregnancy.

background: the renin-angiotensin system is involved in the physiology of pregnancy in two ways. circulating angiotensin ii affects blood pressure, renal hemodynamics, and uteroplacental blood flow. abnormalities in angiotensin ii production rates in hypertensive pregnancy contribute to the hemodynamic changes seen in the disease. additionally, there is a form of the renin-angiotensin system in kidney, ovary, and placenta whose function is regulated by prorenin. prorenin, activated by a specific receptor, is involved in the regulation of steroid hormone biosynthesis and renal and uteroplacental blood flow. the study was conducted in response to a request for applications on research on hypertension in pregnancy jointly released in 1986 by the national heart, lung, and blood institute and the national institute of child health and human development. design narrative: the study was longitudinal in design. measurements were made of glomerular filtration rate, renal plasma flow or uterine blood flow. to define first trimester changes, studies were conducted on in vitro fertilization and ovarian failure patients who had a broad spectrum of plasma prorenins. since interrelated changes in renin and prostaglandins may participate in the pathogenesis of hypertensive pregnancy, raas, prostaglandins, and uteroplacental flow velocity profiles were monitored during a placebo-controlled trial of low-dose aspirin in chronic hypertensives. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
d-cycloserine augmented cbt for panic disorder

Conditions: Panic Disorder

Summary: the purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of panic disorder * at least moderate agoraphobic avoidance exclusion criteria: * psychoactive medication last 6 weeks * exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months * female participant who is pregnant or breast-feeding * lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder * lifetime history of epilepsy or other significant disease or disorder

Keywords: d-cycloserine, cognitive-behaviour therapy, panic disorder
a study of apatinib treatment in for advanced ovarian cancer

Conditions: Ovarian Cancer; Chemotherapeutic Toxicity

Summary: the study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer

ovarian cancer and fallopian tube cancer are common gynecological malignancies in our country. ovarian cancer ranks the second in the incidence of gynecologic malignancies. the mortality rate is the highest. the following three major characteristics exist: first, 70% of the patients are advanced patients; 70% of the patients easy to relapse after treatment; third, 5-year survival rate of about 30%, a serious threat to women's health. our hospital ovarian cancer, tubal cancer patients because of regional constraints, the economy is poor, the more the past, the use of simple chemotherapy, relapse rate and mortality were higher. in the latest national comprehensive cancer network (nccn) guidelines, bevacizumab plus cp is recommended for patients with stage ii, iii, and iv ovarian cancer and fallopian tube cancer, and clinical trials of new drugs are recommended for recurrent / metastatic ovarian cancer. apatinib mesylate is a small molecule vegfr tyrosine kinase inhibitor authored by jiangsu hengrui pharmaceutical co., ltd., whose chemical name is n- \[4- (cyanocyclopentyl) phenylmethane sulfonate \] \[2 - \[(4-picolyl) amino\] (3-pyridyl)\] carboxamide of the formula c25h27n5o3s with a molecular weight of 493.58 (mesylate salt).apatinib can effectively inhibit vegfr-2 at a very low concentration, while higher concentrations can inhibit the action of apatinib, such as platelet-derived growth factor receptor (pdgfr), c-kit and c- the site is the intracellular atp binding site of the protein tyrosine receptor. pharmacodynamic studies show that apatinib can inhibit the vegfr-2 tyrosine kinase activity, blocking vegf signaling after binding, resulting in inhibition of tumor angiogenesis. preclinical studies have shown that apatinib has a strong inhibitory effect on the growth of many human nude mice xenografts such as sarcoma, colorectal cancer, non-small cell lung cancer, gastric cancer and liver cancer and is a broad-spectrum anti-tumor drug.

Eligibility criteria:
inclusion criteria: * pathologically diagnosed as epithelial ovarian cancer, fallopian tube cancer, stage ii-iv period, the expected survival of\> 6 months; * ecog \<2; * liver and kidney function is normal; * no uncontrollable high blood pressure, bleeding, perforation, obstruction. exclusion criteria: * serious cardiopulmonary insufficiency, can not tolerate chemotherapy; * pregnant or lactating women; * 3 years have occurred in other tumors (cervical cancer in situ, has cured basal cell carcinoma, except for bladder epithelial tumors); * allergic to apatinib or its accessories.

Keywords: ovarian cancer
bonami (bone marrow in acute myocardial infarction)

Conditions: Acute and Severe Myocardial Infarction

Summary: emerging evidence suggests that stem cells and progenitor cells derived from bone marrow can be used to improve cardiac function in patients after acute myocardial infarction. in this randomised trial, we aim to assess whether intracoronary transfer of autologous bone-marrow cells could improve myocardial viability at 3 and 12 months' follow-up.

after successful percutaneous coronary intervention (pci) for acute myocardial infarction, 100 patients are randomly assigned to either a control group (n=50) who receives an optimal medical treatment, or a bone-marrow-cell group (n=50) who receives an optimal medical treatment and intracoronary transfer of autologous bone-marrow cells 7•10 days after pci.

Eligibility criteria:
inclusion criteria: * men or women between 18-75 years. * acute myocardial infarction * absence of viability in the infarcted zone and lvef \<45%. exclusion criteria: * history of prior myocardial infarction * significant stenosis in another coronary territory than the acutely treated vessel

Keywords: cell therapy bone marrow mononuclear cells myocardial infarction
levofloxacin as an empirical therapy in patients with complicated urinary tract infections

Conditions: Urinary Tract Infection

Summary: study is planned to evaluate safety and efficacy of levolet in patients with complicated uti

a complicated urinary tract infection is a urinary infection occurring in a patient with a structural or functional abnormality of the genitourinary tract. fluoroquinolones have been recommended as the antimicrobials of choice for the empirical treatment of complicated urinary tract. levofloxacin is a broad spectrum agent, which is known to demonstrate good clinical efficacy against urinary tract infection (uti). there is no published evidence available on the empirical use of levofloxacin 500 mg od and its optimal duration of therapy in patients with complicated urinary tract infections (cuti). the present study evaluates the efficacy and safety, and optimal duration of therapy of levofloxacin 500 mg od in patients with complicated uti.

Eligibility criteria:
inclusion criteria: * men or non-pregnant women over 18 years of age with cuti in * one or more clinical symptoms and signs of a lower uti: fever (\> 38°c, orally), chills, frequency of micturition, dysuria, urge sensation. * one or more of the following underlying conditions suggestive of cuti: * indwelling urinary catheter. * neurogenic bladder. * obstructive uropathy due to lithiasis, tumor or fibrosis. * acute urinary retention in men exclusion criteria: * history of allergy to quinolones * are unable to take oral medication * have an intractable infection requiring \> 14 days of therapy * have a requirement for concomitant administration of sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum or calcium * have prostatitis or epididymitis * have had a renal transplant * have ileal loop or vesica- urethral reflux * have significant liver or kidney impairment * have a history of tendinopathy associated with fluoroquinolones * are pregnant, nursing * have a history of convulsions or cns disorders
pilot study to compare isovue®-250 and visipaque™ 270 for motion artifact and pain in peripheral dsa

Conditions: Peripheral Arterial Occlusive Disease

Summary: the purpose of this study is to compare isovue-250 and visipaque 270 for motion artifact and pain following intraarterial injection for peripheral dsa.


Eligibility criteria:
inclusion criteria: enroll a patient in this study if the patient meets the following inclusion criteria: * provides written informed consent and is willing to comply with protocol requirements; * is at least 18 years of age; * is scheduled to undergo peripheral dsa for the diagnosis and/or treatment (pta) of paod. exclusion criteria: exclude a patient from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed: * is a pregnant or lactating female. exclude the possibility of pregnancy: * by testing on site at the institution (serum or urine βhcg) within 24 hours prior to the start of investigational product administration, * by surgical history (e.g., tubal ligation or hysterectomy), * post menopausal with a minimum 1 year without menses; * has any known allergy to one or more of the ingredients of the investigational products; * has a history of severe congestive heart failure \[class iv in accordance with the classification of the new york heart association (nyha)\] * was previously entered into this study or received an investigational compound within 30 days before admission into this study; * has a history of hypersensitivity to iodinated contrast agents; * has renal impairment (egfr \<60 ml/min/1.73 m2, calculated using the modification of diet in renal disease \[mdrd\] study equation , ); * has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or postdose follow-up examinations.
vascular access for hemodialysis and inflammation

Conditions: Vascular Access for Hemodialysis and Inflammation

Summary: the aim of the present study was to investigate patients free of active infection and/or thrombosis to assess if the type of vascular access (avf, avg, tcc), could influence: 1. the levels of serological markers of inflammation (crp, il-6, tnf-a); 2. the degree of expression on monocyte surface of inflammation and immune response modulating molecules: cd14, cd32 and cd44. 3. the amount of monocytic cells expressing a senescent phenotype (cd14 and cd32).

patients with avf assumed ticlopidine 250 mg/die, patients with tcc and avg assumed warfarin to maintain target inr between 1.8 and 2.5. six wash out consecutive sessions were carried out before starting the study with fresenius fx8 helyxone® , for patients who underwent hd, or with fx 80 helyxone®, for patients who underwent hemodiafiltration (hdf). after the wash out period, fresh whole blood and serum samples were drawn on starting dialysis, during the midweek hd session for 4 consecutive weeks. for each patient the mean value of the 4 blood samples was considered. all patients continued hd or hdf with fx8 or fx 80 helyxone® during the whole study period.in order to estimate the normal ranges of the parameters that we evaluated, 60 anonymous healthy volunteers were also submitted to the same assays.

Eligibility criteria:
inclusion criteria: * all the patients recruited for the study were infection and thrombosis free from almost 6 months. * no patients included had autoimmune disease, hepatic failure, diabetes or malignancy. * patients were not administered ace inhibitors, angiotensin receptor antagonists, antiinflammatory or immunosuppressive drugs. * all the patients had residual gfr \< 5 ml/min. * the vascular access considered were placed from at least 6 months. exclusion criteria: * patients with recirculating vascular access \> 10% were excluded from the study. * patients with acute cardiovascular accident in the last 15 days before starting the study.

Keywords: avf avg tcc inflammation monocite senescence
the efficacy of l-carnitine in the management of acute carbon monoxide poisoning

Conditions: Carbon Monoxide Poisoning

Summary: carbon monoxide (co) poisoning results in high morbidity and mortality worldwide. co is described as a "silent killer" because co is colorless, odorless, and tasteless but highly toxic. the diagnosis of acute co poisoning depends on the history of exposure to a source of fire in a closed space along with the clinical and laboratory findings. the pathophysiology of co poisoning is not fully understood; however, it is proved that co induces hypoxia by forming carboxyhemoglobin (cohb) and shifting the oxygen dissociation curve to the left. the molecular mechanisms of co poisoning include oxidative injury through the generation of free radicals. in addition, oxygen therapy might enhance the reactive oxygen species (ros) production and result in reperfusion injury. free radicals could induce a serious impact on vital organs, including the heart, and brain. l-carnitine is an endogenous mitochondrial constituent that contributes to normal mitochondrial activities. l-carnitine is an antioxidant with potent ros scavenging ability. ros-mediated pathology of co suggests that antioxidants are potentially useful agents in the alleviation of co toxicity. thus, the current study will investigate the therapeutic efficacy of l-carnitine in improving the prognosis of acute co poisoning. the current clinical trial will include patients with moderate and severe acute carbon monoxide poisoning according to poisoning severity score.

a randomized clinical trial (phase ii) will be conducted at alexandria main university hospital. the total required sample size is 72. the sample size was calculated by g power 3.1.9.4 software program depending on the primary outcome. according to these assumptions: effect size, defined as the difference between group 1 and group 2 in the mean troponin levels at 24 hr, was calculated according to sun et al. (2011) and was 0.657, alpha error =0.05, power of 80%, allocation ratio 1:1. a 20% expected attrition was added to the sample size to account for loss to follow-up. so, the final sample size was 72; 36 patients per group. all patients will be subject to the following: 1. history taking: * personal data: age, and sex. * exposure-related data: circumstances of exposure, and time till hospitalization. * past medical history. 2. clinical assessment: * glasgow coma scale, vital signs, and general examination. * laboratory investigations: arterial blood gases (abg), carboxy hemoglobin level (cohb), and cardiac enzymes (cpk, ck-mb, troponin). * electrocardiogram (ecg).

Eligibility criteria:
inclusion criteria: * the current clinical trials will include patients with moderate and severe acute carbon monoxide poisoning according to poisoning severity score. exclusion criteria: * when the diagnosis of acute carbon monoxide poisoning is unconfirmed. * patients with advanced cardiac and neurological diseases.

Keywords: carbon monoxide poisoning cardiotoxicity troponin l-carnitine outcome
intra-articular injection of msc-derived exosomes in knee osteoarthritis (exooa-1)

Conditions: Osteoarthritis, Knee

Summary: the study aim to evaluate safety of exosomes (sevs) from allogeneic mesenchymal stromal cells delivered by an intra-articular injection in the knee of patients with mild to moderate symptomatic osteoarthritis. the sevs will be produced in a gmp-facility. we expect to enrolle 10 patients in this phase 1 trial and the follow-up will be up to 12 months.


Eligibility criteria:
inclusion criteria: * symptomatic knee oa with vas \>50mm * knee oa kellgren-lawrence grade ii to iii * chondromalacia grade i to iii * stable joint exclusion criteria: * bilateral symptomatic knee oa * local infection * neoplasia * joint replacement * recent use of local steroids * bmi \> 30
transcriptional framework for the molecular diagnosis of response to immunotherapy in lung cancer with agnostic potential

Conditions: NSCLC

Summary: through genomic and transcriptomic sequencing techniques (whole exome sequencing, wes; whole transcriptome sequencing, wts) patients with enrichment for keapness and specific gene interactions associated with it.

retrospective-prospective, non-pharmacological, biological, multicenter observational study, for which the collection and use of tissue samples from patients suffering from nsclc and/or other tumor types. through genomic and transcriptomic sequencing techniques (whole exome sequencing, wes; whole transcriptome sequencing, wts) patients with enrichment for keapness and specific gene interactions associated with it. subsequently, through the same techniques, applied to different tumor regions taken from operating site it will be possible to identify the evolution of the tumor at a spatio-temporal level and the immune subtype associated with the presence/absence of keapness. finally, cell lines will be used to recapitulate what was observed in the patient and per-patient cohorts identify new pharmacological vulnerabilities associated with the characteristics of keapness.

Eligibility criteria:
inclusion criteria cohort (nsclc-ic): * age \>18 years; * histological diagnosis of nsclc * metastatic disease * availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (surgical or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy); * ecog ps 0-2; * adequate hematological, hepatic and renal function; * measurable disease according to recist criteria * availability of follow-up data for at least 6 months and/or until death/progression exclusion criteria cohort (nsclc-ic): * previous systemic therapy for metastatic disease; * comorbidities not controlled with adequate medical therapy. inclusion criteria nsclc-vc cohort: * age \>18 years; * histological diagnosis of nsclc * metastatic disease * availability, at the time of enrollment, of adequate biological material to be able to perform molecular analyses, taken (during surgery and/or by biopsy) before administration of any anti-tumor treatment (chemotherapy and/or radiotherapy); * ecog ps 0-2; * adequate hematological, hepatic and renal function; * measurable disease according to recist criteria; * written informed consent (participation in the study and data processing) exclusion criteria nsclc-vc cohort: * previous systemic treatment for metastatic disease; * comorbidities not controlled with adequate medical therapy;
nirs and do2i correlation

Conditions: Multiorgan Failure; Perfusion; Complications

Summary: this study evaluates the association between near infrared spectroscopy (nirs) and indexed oxygen delivery (do2i) and their possible correlation with postoperative organ failure.

literature evidences show that levels of do2i under 262-272 ml/min/m2 during cardiopulmonary by-pass (cpb) are associated with an increased incidence of acute kidney injury (aki). furthermore, it has been demonstrated that keeping a nirs of 75-80% compared to the basal value reduces the risk of perioperative morbidity. on the other hand, a nirs \< 50% of basal value seems to be predictive of an increase in morbidity. all of those studies had been performed during cpb and knowledge lacks in management of do2i and nirs before and after cpb.

Eligibility criteria:
inclusion criteria: * all patients undergoing cardiac surgery with cardiopulmonary by-pass whose have been signed the consent informed exclusion criteria: * impossibilty to collect a correct continuous cardiac output measure with picco (chronic atrial fibrillation or severe peripheral vasculopaty)

Keywords: nirs do2
intravenous streptokinase in acute myocardial infarction

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia

Summary: to determine whether the administration of intravenous streptokinase (sk) early in the course of acute, transmural myocardial infarction would limit myocardial damage.

background: determination of the potential value of thrombolytic therapy in patients with acute myocardial infarction was an issue of major importance in 1983. an estimated 1.4 million heart attacks occurred each year, of which over 500,000 were fatal. reduction of mortality required an effective means to reduce infarct size. studies indicated that reperfusion represented a potent means of achieving salvage of ischemic myocardium. pilot clinical studies indicated that reperfusion could be achieved in a substantial percentage of patients by lysis of coronary thrombosis with both intracoronary and intravenous streptokinase administration. intracoronary thrombolysis was receiving widespread clinical applications but had many limitations. the intracoronary route took 90-120 minutes longer to administer than the intravenous route. because intracoronary therapy required the availability of a catheterization laboratories and highly skilled invasive cardiologists, this treatment was not available to large numbers of patients who were hospitalized in smaller community hospitals. design narrative: randomized design with two groups and fixed sample size. control patients received routine coronary care. the treatment group received intravenous streptokinase plus conventional care. this was followed with intravenous heparin and warfarin. the primary endpoint was 14 day mortality. secondary endpoints included angiographic patency of the involved coronary artery at 10 to 14 days, left ventricular function, segmental wall motion analysis, and myocardial infarction size at 30-45 days.

Eligibility criteria:
men and women, aged less than 75. myocardial infarction onset within six hours.
study of 2 doses of hrv vaccine given concomitantly or separately with routine vaccinations in healthy infants in usa

Conditions: Infections, Rotavirus

Summary: the aim of this this study is to confirm absence of immune interference between hrv vaccine and routine infant vaccinations currently in use in the usa.

a phase iii randomized multi-center study to assess the immunogenicity of three doses of pediarix®, prevnar® and acthib® given to healthy infants at 2, 4 and 6 months of age when administered with glaxosmithkline (gsk) biologicals' two-dose oral live attenuated human rotavirus (hrv) vaccine given during the same vaccination visit (at 2 and 4 months of age) or given separately (at 3 and 5 months of age).

Eligibility criteria:
inclusion criteria: * healthy infants 6 -12 weeks old at dose 1 with written informed consent. exclusion criteria: * allergic reaction to vaccine components; * clinically significant history of chronic gi disease (uncorrected gi congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol; * immunocompromised.

Keywords: hrv vaccine diarrhoea rotavirus